PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of death worldwide. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed budget impact analysis on the basis of two bronchodilators in Russian Federation – tiotropium bromide (Spiriva) and ipratropium bromide (Atrovent) in COPD treatment. Changing treatment option from Atrovent to Spiriva provides economic benefit and permit to treat additionallyCOPD patients for the same period.

Keywords

• pharmacoeconomic analysis
• chronic obstructive pulmonary disease
• tiotropium bromide
• spiriva ipratropium bromide
• atrovent, budget impact analysis